Notes in Gastrointestinal stromal tumours

To Subscribe, use this Key

Status	Last Update	Fields
Published	02/18/2024	GI \| GIST \| 1.1 \| Overview / definition / histogenesis
Published	02/18/2024	GI \| GIST \| 1.2 \| Epidemiology
Published	02/18/2024	GI \| GIST \| 1.3.1 \| Risk factors
Published	02/18/2024	GI \| GIST \| 1.3.3 \| Carney-Stratakis syndrome and Carney's triad
Published	02/18/2024	GI \| GIST \| 1.3.2 \| Neurofibromatosis type 1 (NF1)
Published	02/18/2024	GI \| GIST \| 1.4 \| Pathogenesis
Published	02/18/2024	GI \| GIST \| 1.5 \| Macroscopic and microscopic appearance
Published	02/18/2024	GI \| GIST \| 1.6 \| Biologic behaviour
Published	02/18/2024	GI \| GIST \| 1.7 \| Prognostic factors
Published	02/18/2024	GI \| GIST \| 2.1 \| Workup
Published	02/18/2024	GI \| GIST \| 1.8 \| Clinical presentataion
Published	02/18/2024	GI \| GIST \| 2.2 \| Differential diagnosis
Published	02/18/2024	GI \| GIST \| 2.3 \| Staging
Published	02/18/2024	GI \| GIST \| 2.4 \| NIH risk groups (Boston)
Published	02/18/2024	GI \| GIST \| 3.2 \| Management \| General
Published	02/18/2024	GI \| GIST \| 3.3 \| Management \| Surgery
Published	02/18/2024	GI \| GIST \| 3.4 \| Management \| Imatinib
Published	02/18/2024	GI \| GIST \| 3.7 \| Management \| Radiotherapy
Published	02/18/2024	GI \| GIST \| 3.1 \| Management \| Overview
Published	02/18/2024	GI \| GIST \| 3.5 \| Managment \| Sunitinib (second line)
Published	02/18/2024	GI \| GIST \| 3.6 \| Management \| Regorafenib (third line)
Published	02/18/2024	GI \| GIST \| 3.8 \| Management \| Metasatic disease
Published	02/18/2024	GI \| GIST \| 3.9 \| Management by subsite
Published	02/18/2024	GI \| GIST \| 4 \| Follow up / response assessment
Status	Last Update	Fields